Your browser doesn't support javascript.
loading
Plasma levels of thrombin and activated protein C in patients with acute myocardial Infarction: An observational study.
Becher, Tobias; Schimanski, Robert; Müller, Jens; Baumann, Stefan; Klenantz, Selina; Pötzsch, Bernd; Lossnitzer, Dirk.
Afiliação
  • Becher T; First Department of Medicine (Division of Cardiology), University Medical Center Mannheim, Mannheim, Germany.
  • Schimanski R; DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Mannheim, Germany.
  • Müller J; University of Heidelberg, Department of Cardiology, Angiology and Pneumology, Heidelberg, Germany.
  • Baumann S; First Department of Medicine (Division of Cardiology), University Medical Center Mannheim, Mannheim, Germany.
  • Klenantz S; Institute for Experimental Haematology and Transfusion Medicine, University of Bonn Medical Center (UKB), Bonn, Germany.
  • Pötzsch B; First Department of Medicine (Division of Cardiology), University Medical Center Mannheim, Mannheim, Germany.
  • Lossnitzer D; DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Mannheim, Germany.
Int J Cardiol Heart Vasc ; 42: 101097, 2022 Oct.
Article em En | MEDLINE | ID: mdl-35928794
ABSTRACT

Introduction:

Activation of the plasmatic coagulation system is a major contributor to acute myocardial infarction (AMI). Markers of plasmatic coagulation and thrombin activation are correlated with clinical, laboratory and outcome parameters. In this study, we sought to evaluate if the catalytically active coagulation factors thrombin and activated protein C (APC) can be measured in patients with AMI and whether there are associations with laboratory or clinical parameters.

Methods:

Thrombin and APC was quantified using oligonucleotide-enzyme-capture assays (OECAs) in 132 patients presenting with AMI immediately before and 24 h after percutaneous coronary intervention (PCI).

Results:

APC was measured above the lower limit of quantification (LLOQ) in 43 (32.6%) patients before PCI (day 0) and in 55 (41.7%) patients on the following day (day 1). Thrombin was measured in 62 (47.0%) patients on day 0 and 60 (45.5%) on day 1. Both APC and thrombin were correlated with markers of thrombin generation including F1 + 2 and TAT. Additionally, APC values correlated with CK and CK-MB while thrombin correlated with CK and troponin I after PCI. APC levels above a cutoff of 0.141 ng/ml after PCI, but not thrombin, predicted 30 day major adverse cerebrovascular events.

Conclusion:

Both thrombin and APC were elevated above the LLOQ in a subset of patients with AMI before and after PCI and correlated with surrogate markers of myocardial injury. Our results indicate that enzymatically active APC and thrombin are present in the circulation of patients with AMI.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies Idioma: En Revista: Int J Cardiol Heart Vasc Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies Idioma: En Revista: Int J Cardiol Heart Vasc Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha